Incyte Corporation (INCY)

$94.22 (As of 08/12/20)

Price Target (6-12 Months): **$99.00**

Long Term: 6-12 Months	**Zacks Recommendation:** (Since: 06/03/20) Prior Recommendation: Underperform	**Neutral**
Short Term: 1-3 Months	**Zacks Rank:** (1-5)	**3-Hold**
	Zacks Style Scores:	VGM:B
	Value: C | Growth: A | Momentum: C	

Summary

Incyte's performance in the second quarter was impressive as demand for Jakafi in all three approved indications (polycythemiavera, myelofibrosis and the recent label expansion in acute GVHD) continues to boost sales. The company's efforts to diversify its revenue base are encouraging as well and the label expansion of Jakafi in additional indications will further boost sales. Incyte's efforts to develop its pipeline forming strategic collaborations are encouraging. The recent approval of Pemazyre, Monjuvi (with MorphoSys) and Tabrecta (with Novartis) will bring additional sales. However, pipeline setbacks are concerning. Moreover, the company is highly dependent on Jakafi for a major chunk of revenues. The recently-approved therapies will pose stiff competition to Jakafi. Shares have outperformed the industry in the past year.

Price, Consensus & Surprise

Data Overview

52 Week High-Low	**$110.37 - $62.48**
20 Day Average Volume (sh)	**1,228,762**
Market Cap	**$20.6 B**
YTD Price Change	**7.9%**
Beta	**1.00**
Dividend / Div Yld	**$0.00 / 0.0%**
Industry	**Medical - Biomedical and Genetics**
Zacks Industry Rank	**Bottom 35% (164 out of 253)**
Last EPS Surprise	**61.0%**
Last Sales Surprise	**15.5%**
EPS F1 Est- 4 week change	**13.2%**
Expected Report Date	**11/03/2020**
Earnings ESP	**0.0%**
P/E TTM	**NA**
P/E F1	**NA**
PEG F1	**NA**
P/S TTM	**8.6**

Sales and EPS Growth Rates (Y/Y %)



Sales Estimates (millions of $)

	Q1	Q2	Q3	Q4	Annual*
2021	622 E	693 E	728 E	808 E	2,825 E
2020	569 A	688 A	623 E	660 E	2,527 E
2019	498 A	530 A	552 A	579 A	2,159 A

EPS Estimates

	Q1	Q2	Q3	Q4	Annual*
2021	$0.77 E	$0.91 E	$0.97 E	$1.22 E	$3.77 E
2020	-$2.86 A	$1.24 A	$0.73 E	$0.76 E	-$0.29 E
2019	$0.62 A	$0.75 A	$0.82 A	$0.65 A	$2.83 A

*Quarterly figures may not add up to annual.

The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 08/12/2020. The reports text is as of 08/13/2020.

Overview

Wilmington, DE-based Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland.



Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera ("PV"),who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. The drug is also approved in the United States for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older. While Incyte markets the drug in the United States, it is marketed by Novartis as Jakavi outside the country. Jakafi sales came in at $1.7 billion in 2019, thereby contributing 78% to total revenues.

The company's second JAK1 and JAK2 inhibitor, Olumiant (baricitinib, JAK1/JAK2 inhibitor) was approved in the EU in Feb 2017 for rheumatoid arthritis (RA). Incyte is co-developing Olumiant with Eli Lilly. In June 2018, the FDA approved the 2mg dose of baricitinib as Olumiant for the treatment of adults with RA. The approval brings another source of income for Incyte as royalties.

In Jun 2016, Incyte entered into a share purchase agreement with ARIAD under which it gained the latter's European business and the rights to Iclusig in the EU and 22 other countries including Switzerland, Norway, Turkey, Israel and Russia. Revenues for 2019 came in at $2.2 billion, up from $1.9 billion in 2018.

Reasons To Buy:

Key growth driver, Jakafi, has been performing well. Incyte's efforts to develop its pipeline are also encouraging.

- **Share Price Performance:** Incyte's stock has outperformed the industry in the past one year.

- **Jakafi Driving Growth**: Jakafi continues to drive growth for the company on label expansions. It became the first FDA-approved JAK inhibitor for any indication, and the first and only product to be approved by the FDA for the treatment of MF and PV — rare blood cancers. Jakafi is the only treatment to provide consistent hematocrit control, spleen volume reduction and complete hematological remission by targeting the overactive JAK pathway. Its label has been updated several times since approval, which has boosted Incyte's sales. We note that Jakafi enjoys the Orphan Drug status in the United States for MF, PV and essential thrombocythemia. The drug also has a long patent life that runs until late 2027.

  In order to expand the patient population and increase the commercial potential of the drug, the company is working on expanding the drug's label further. The FDA recently approved Jakafi for the treatment of steroid-refractory acute GVHD in adult and pediatric patients aged 12 years or older. This is the third indication, for which the drug has been approved in the United States. The label expansion of the drug will further boost sales. Meanwhile, REACH2 and REACH3, evaluating steroid-refractory acute and steroid-refractory chronic graft-versus-host disease, respectively, are ongoing in collaboration with Novartis. REACH2, the phase III study evaluating Jakafi in patients with steroid-refractory acute GVHD, met its primary endpoint of superior overall response. An Independent Data Monitoring Committee (IDMC) recommended that the phase III REACH3 trial should continue without modification following an interim efficacy and safety analysis. REACH3 study, evaluating ruxolitinib in patients with steroid-refractory GVHD also met its primary endpoint of ORR at month 6 and both key secondary endpoints (modified Lee symptom scale and failure-free survival).

  Moreover, the cream formulation is currently in phase III development for the treatment of patients with mild to moderate atopic dermatitis (TRuE-AD). It is also being evaluated for the treatment of adolescents and adults with vitiligo (TRuE-V). Both the TRuE-AD1 and TRuE-AD2 phase III studies of ruxolitinib cream in patients with mild-to-moderate atopic dermatitis are proceeding as planned and the NDA submission is expected at the end of 2020. Incyte plans to initiate pivotal trials of the combination of ruxolitinib and parsaclisib as both first-line therapy for MF patients and MF patients with an inadequate response to ruxolitinib monotherapy.

  Meanwhile, Incyte initiated a phase III study, RUXCOVID, to evaluate the efficacy and safety of Jakafi plus standard-of-care (SoC) compared to SoC therapy alone in patients with COVID-19-associated cytokine storm. The company is also opening a second phase III study in the United States to evaluate the efficacy and safety of Jakafi plus SoC compared to SoC therapy alone in COVID-19 patients on mechanical ventilation and who have acute respiratory distress syndrome (ARDS), a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs.

- **Approval of Additional Drugs Bode Well**: Incyte's pipeline is highly encouraging. The company has several candidates in early-to mid-stage development, including both targeted therapies and immune therapies that are being developed in oncology and outside oncology. The FDA recently approved pemigatinib, a kinase inhibitor indicated for the treatment of adults with previously-treated, unresectable, locally-advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. The candidate has been approved under the brand name, Pemazyre. Approval of new drugs will reduce Incyte's dependence on lead drug, Jakafi. The marketing authorization application (MAA) seeking approval for pemigatinib in Europe is under review with the European Medicines Agency (EMA).

  Pemazyre is also being evaluated in other studies for various other indications — myeloproliferative neoplasms and in previously-treated, locally-advanced/metastatic or surgically unresectable solid tumor malignancies. A phase III study is also ongoing to evaluate the drug as a first-line treatment for patients with cholangiocarcinoma with FGFR2 fusions or rearrangements. It is also being evaluated in a phase II study in combination with Keytruda and as monotherapy in patients with previously-untreated, metastatic or unresectable bladder cancer harboring FGFR3 mutations or fusions/rearrangements, who are not eligible to receive cisplatin.

  The FDA recently approved Tabrecta (capmatinib) for treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14) as detected by an FDA-approved test. Novartis has exclusive worldwide development and commercialization rights to Tabrecta and the FDA approval of the drug triggers $70 million in milestone payments from Novartis. Incyte is also eligible to receive 12-14% royalties on net sales of Tabrecta from Novartis. The drug was recently approved in Japan. In July 2020, the FDA approved Monjuvi (tafasitamab-cxix), an Fc-engineered anti-CD19 antibody, in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and who are not eligible for autologous stem cell transplant (ASCT). Incyte and MorphoSys will co-commercialize Monjuvi in the United States. These new approvals will bring additional source of income for the company.

  Preparations are ongoing to initiate the phase III POD1UM-304 study of retifanlimab (formerly INCMGA0012) in combination with platinum-based chemotherapy as a first-line treatment for patients with non-small cell lung cancer (NSCLC).

- **Encouraging Collaborations**: Incyte has two major agreements with Novartis and Lilly. The 2009 agreement with Novartis includes Jakafi (excluding topical formulations). Per the agreement, Incyte is marketing Jakafi in the United States while Novartis is responsible for the same outside the United States. The deal with Eli Lilly gives the latter exclusive worldwide development and commercialization rights to Olumiant. The FDA approval of Olumiant has triggered a $100 million milestone payment from Lilly. However, Incyte has elected to not participate in the development of baricitinib in order to reallocate capital, over time, to other promising internal projects. Nevertheless, it will continue to receive royalties on global net sales of Olumiant, pursuant to the terms of its agreement with Lilly. The collaboration and license agreement with MorphoSys for the development and commercialization of tafasitamab became effective in March 2020. The FDA has granted Priority Review to tafasitamab in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), and set a PDUFA goal date of Aug 30, 2020.

- **Favorable Debt Profile**: As of Jun 30, 2020, Incyte' total debt to total capital ratio stood at 2.5X, which compares favorably to the industry's 50.9X. A lower ratio indicates lower financial risk and vice versa. The company has a sound cash position too with cash, equivalents and

marketable securities of $1.0 billion with a long-term debt of $32 million.

Reasons To Sell:

- **Overdependence on Jakafi for Growth**: Incyte's dependence on a single product, Jakafi for growth is concerning. Lower-than-expected sales would be a huge setback for the company. While we are positive on the company's efforts to expand Jakafi's label, any development/regulatory setback could pull down the stock significantly.

- **Pipeline Setbacks**: Though we are pleased with Incyte's broad pipeline, the candidates still have to go a long way before hitting the market. Any hiccup in the development process or adverse study results may weigh heavily on the stock and hamper the company's growth progress.

> Overdependence on Jakafi is concerning. Also, most of its pipeline candidates are in early-to-mid stages of development, which translates into a long way to approval.

The phase III GRAVITAS-301, evaluating itacitinib in combination with corticosteroids in patients with treatment-naïve (first-line) acute GVHD, did not meet the primary endpoint of overall response rate (ORR) at day 28 compared to placebo plus corticosteroids. Incyte earlier suffered a setback with epacadostat. The external Data Monitoring Committee (eDMC) review of the pivotal phase III study, ECHO-301, evaluating epacadostat in combination with Keytruda in patients with unresectable or metastatic melanoma determined that the study did not meet the primary endpoint of improving progression-free survival in the overall population compared to pembrolizumab monotherapy. Consequently, based on the disappointing data and the recommendation of the eDMC, Incyte stopped the study to enable patients and their physicians to consider alternative therapeutic options.

- **Stiff Competition**: The FDA recently approved Inrebic for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis. This will increase competition for Jakafi. Additionally, Jakafi is likely to face competition from generics. Also, Iclusig faces intense competition. Meanwhile, the oncology market is attracting a lot of attention, with several companies inking deals to tap into this high revenue-potential market.

Last Earnings Report

Incyte Beats on Q2 Earnings and Sales on Strong Jakafi

Quarter Ending	06/2020
Report Date	**Aug 04, 2020**
Sales Surprise	**15.50%**
EPS Surprise	**61.04%**
Quarterly EPS	**1.24**
Annual EPS (TTM)	**-0.15**

Incyte reported an adjusted earnings of $1.24 per share, easily beating the Zacks Consensus Estimate of earnings of 77 cents. The company had reported adjusted earnings of 75 cents in the year-ago quarter.

Including milestones and contracts, revenues came in at $688.04 million, which grew 30% year over year and beat the Zacks Consensus Estimate of $599.45 million.

Quarter in Detail

Total product-related revenues came in at $593 million, up 16% from the year-ago quarter. Jakafi revenues came in at $473.7 million, increasing 16% from the year-ago quarter and beating the Zacks Consensus Estimate of $471 million. Robust demand for Jakafi in all three approved indications drove revenues.

Net product revenues of Iclusig amounted to $22.8 million, down from $24.4 million in the year-ago quarter.

Jakavi (name outside the United States) royalty revenues from Novartis AG for commercialization in ex-U.S. markets grew 16% to $66.2 million. Olumiant's product royalty revenues from Eli Lilly came in at $25.8 million, up 35%.

R&D expenses were $254.1 million, down from $261.7 million in the year-ago quarter. SG&A expenses amounted to $104.4 million, up from $93.1 million in the prior-year quarter.

2020 Guidance Reaffirmed

The company maintained its previously-provided guidance for 2020. The company expects Jakafi revenues of $1,880-$1,950 million for 2020. Iclusig revenues are projected around $100-$105 million.

Pipeline Update

In July, the FDA granted approval to Monjuvi (tafasitamab-cxix), an Fc-engineered anti-CD19 antibody, in combination with Revlimid for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and who are not eligible for autologous stem cell transplant (ASCT). Please note that Incyte entered into a global collaboration with MorphoSys for the development and commercialization of tafasitamab. Incyte and MorphoSys will co-commercialize Monjuvi in the United States.

In May 2020, Incyte and partner Novartis obtained FDA approval of Tabrecta (capmatinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14) as detected by an FDA-approved test.

In April, the FDA approved Incyte's selective FGFR inhibitor, Pemazyre (pemigatinib), for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test.

The REACH3 study, evaluating ruxolitinib in patients with steroid-refractory chronic graft-versus-host disease (GVHD), met its primary endpoint of overall response rate (ORR) at month 6 and both key secondary endpoints (modified Lee symptom scale and failure-free survival). The company also plans to file a new drug application seeking approval for ruxolitinib cream, a new formulation of its key drug Jakafi, as a treatment for mild-to-moderate atopic dermatitis by the end of 2020.

Recent News

Monjuvi Gets FDA Approval – July 31

Incyte and MorphoSys announced that the FDA has approved Monjuvi (tafasitamab-cxix) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).

Reports Positive Data on Jakafi – July 23

Incyte announced that the late-stage study, REACH3, evaluating Jakafi in patients with moderate or severe steroid-refractory or steroid dependent chronic graft-versus-host disease (GVHD) met its primary endpoint of superior overall response rate (ORR) at week 24 compared to best available therapy (BAT). In addition, the study met both key secondary endpoints, significantly improving failure-free survival (FFS) and patient-reported symptoms assessed by the modified Lee chronic GVHD symptom scale (mLSS).

Approval of Tabrecta in Japan – June 29

Incyte announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Tabrecta (capmatinib) for MET exon 14 skipping (METex14) mutation-positive advanced and/or recurrent unresectable non-small cell lung cancer (NSCLC). Tabrecta is approved for first-line and previously treated patients, regardless of prior treatment type.

Tabrecta is the third Incyte-discovered medicine to receive approval in Japan. Its partner Novartis has exclusive worldwide development and commercialization rights to Tabrecta. The approval of the drug in Japan triggers a $20-million milestone payment to Incyte. The company is also eligible to receive 12-14% royalties on global net sales of Tabrecta by Novartis.

Valuation

Incyte's shares are up 9.4% in the year-to-date period and 17.7% over the trailing 12-month period. Stocks in the Zacks sub-industry and the Zacks Medical sector are up 3.9% and 1.4% in the year-to-date period, respectively. Over the past year, the Zacks sub-industry is up 18.3% while the sector is up 11.1%.

The S&P 500 index is up 4.8% in the year-to-date period and 19.1% in the past year.

The stock is currently trading at 7.6X forward 12-month sales per share which compares to 2.78X for the Zacks sub-industry, 2.84X for the Zacks sector and 3.7X for the S&P 500 Index.

Over the past five years, the stock has traded as high as 27.64X and as low as 5.35X, with a 5-year median of 10.54X. Our Neutral recommendation indicates that the stock will perform in-line with the market. Our $99 price target reflects 8.0X forward 12-month sales per share.

The table below shows summary valuation data for INCY

Valuation Multiples - INCY

		Stock	Sub-Industry	Sector	S&P 500
P/S F12M	Current	7.6	2.78	2.84	3.7
	5-Year High	27.64	3.23	3.41	3.7
	5-Year Low	5.35	1.93	2.22	2.53
	5-Year Median	10.54	2.75	2.89	3.05
P/B TTM	Current	8.79	2.87	4.42	4.71
	5-Year High	426.7	6.01	5.07	4.71
	5-Year Low	5.24	2.06	2.94	2.83
	5-Year Median	11.48	3.87	4.3	3.74

As of 08/12/2020

Industry Analysis **Zacks Industry Rank:** Bottom 35% (164 out of 253)

Top Peers

Company (Ticker)	Rec	Rank
Emergent Biosolutions Inc. **(EBS)**	Outperform	1
Horizon Therapeutics Public Limited Company **(HZNP)**	Outperform	1
QIAGEN N.V. **(QGEN)**	Outperform	1
Alkermes plc **(ALKS)**	Neutral	3
SWEDISH ORP BIO **(BIOVF)**	Neutral	3
BioMarin Pharmaceutical Inc. **(BMRN)**	Neutral	3
Bristol Myers Squibb Company **(BMY)**	Neutral	3
SINO PHARMACEUT **(SBMFF)**	Neutral	NA

Industry Comparison Industry: Medical - Biomedical And Genetics

Industry Peers

	INCY	X Industry	S&P 500	BMRN	BMY	QGEN
Zacks Recommendation (Long Term)	Neutral	-	-	Neutral	Neutral	Outperform
Zacks Rank (Short Term)	3	-	-	3	3	1
VGM Score	B	-	-	B	A	D
Market Cap	20.61 B	261.38 M	23.75 B	21.40 B	144.00 B	11.03 B
# of Analysts	6	2.5	14	9	7	2
Dividend Yield	0.00%	0.00%	1.68%	0.00%	2.83%	0.00%
Value Score	C	-	-	D	A	C
Cash/Price	0.07	0.22	0.07	0.06	0.16	0.08
EV/EBITDA	35.07	-3.77	13.35	660.29	24.43	42.92
PEG Ratio	NA	1.93	2.98	NA	1.18	1.04
Price/Book (P/B)	8.79	3.99	3.20	6.61	2.93	4.21
Price/Cash Flow (P/CF)	37.65	16.95	12.97	185.23	14.50	18.23
P/E (F1)	NA	25.34	22.17	76.53	10.21	23.17
Price/Sales (P/S)	8.63	16.08	2.54	11.59	4.13	6.84
Earnings Yield	-0.31%	-13.50%	4.31%	1.30%	9.81%	4.32%
Debt/Equity	0.01	0.01	0.77	0.33	0.85	0.53
Cash Flow ($/share)	2.50	-1.07	6.94	0.64	4.39	2.66
Growth Score	A	-	-	A	A	D
Hist. EPS Growth (3-5 yrs)	52.48%	17.80%	10.41%	NA	23.36%	9.09%
Proj. EPS Growth (F1/F0)	-110.25%	15.46%	-6.32%	65.83%	32.96%	46.15%
Curr. Cash Flow Growth	132.41%	14.65%	5.22%	200.25%	36.74%	9.25%
Hist. Cash Flow Growth (3-5 yrs)	140.30%	7.73%	8.55%	27.84%	22.46%	5.76%
Current Ratio	3.73	5.69	1.33	3.26	1.47	1.71
Debt/Capital	1.34%	3.38%	44.59%	24.90%	45.99%	34.82%
Net Margin	-8.00%	-201.60%	10.13%	6.62%	-1.61%	0.86%
Return on Equity	-8.06%	-59.21%	14.59%	4.37%	28.47%	15.85%
Sales/Assets	0.76	0.18	0.51	0.38	0.31	0.31
Proj. Sales Growth (F1/F0)	17.06%	5.03%	-1.40%	12.50%	59.66%	16.47%
Momentum Score	C	-	-	C	F	F
Daily Price Chg	1.33%	0.00%	0.67%	1.02%	0.81%	-0.57%
1 Week Price Chg	-1.85%	3.55%	2.30%	-0.95%	4.02%	-4.33%
4 Week Price Chg	-9.62%	-1.64%	4.87%	-6.88%	7.37%	4.58%
12 Week Price Chg	-4.17%	2.66%	13.54%	25.50%	3.18%	12.24%
52 Week Price Chg	16.24%	12.67%	6.06%	64.58%	39.44%	39.94%
20 Day Average Volume	1,228,762	346,642	2,006,991	976,546	10,195,973	1,831,256
(F1) EPS Est 1 week change	0.00%	0.00%	0.00%	3.48%	0.83%	0.00%
(F1) EPS Est 4 week change	13.18%	0.00%	1.95%	17.82%	1.12%	4.50%
(F1) EPS Est 12 week change	30.00%	1.47%	2.72%	23.96%	1.42%	35.06%
(Q1) EPS Est Mthly Chg	-30.30%	0.00%	0.84%	-41.67%	-2.99%	1.82%

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	C
Growth Score	A
Momentum Score	C
VGM Score	B

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock.The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment.This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time.ZIR is not a broker-dealer.ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients.Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.